STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Pharma Job Slowdown, Diet Drugs Boosting GDP, And More
The widespread use of new weight loss drugs in the U.S. could boost gross domestic product by 1% through a boost in workplace efficiency.
STAT1 min readSecurity
STAT+: UnitedHealth Cyberattack Impedes Pharmacies’ And Hospitals’ Ability To Process Insurance Claims
Hospitals and pharmacies are stuck in an insurance processing logjam after a cyberattack on UnitedHealth's Change Healthcare.
STAT1 min read
STAT+: Annovis Bio Delivers Candor On Its Parkinson’s Study, Even If It Doesn’t Inspire Much Confidence
Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About India-made Versions Of Wegovy, An RSV Vaccine Scramble, And More
Indian drugmakers aiming to grab a slice of the weight loss treatment sales pie are developing their own versions of Novo Nordisk's Wegovy.
STAT1 min read
STAT+: DarioHealth Acquires Twill, Hoping It’s A Shortcut To Profitability
DarioHealth, with apps for managing chronic diseases, will acquire mental health app maker Twill, hoping to attract large customers and become profitable.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A CEO Change At AbbVie, A Long-acting HIV Drug, And More
AbbVie announced that CEO Richard Gonzalez, who has managed its ascent since being spun off from Abbott Laboratories in 2013, will step down in July.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Weight Loss Drugs, A Cell Therapy For Melanoma, And More
China has more obese people than anywhere else in the world, and they are increasingly turning to weight loss drugs, fueling a gray market.
STAT1 min read
STAT+: Leading MD Anderson Oncologist Disputes Junior Scientist’s Claims In Lawsuit Over Research Credit
Padmanee Sharma, one of MD Anderson's most influential scientists, is disputing a lawsuit filed by a junior researcher in a contentious case over research credit.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Kids Taking Wegovy, Telehealth For Abortion Pills, And More
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's Wegovy weight loss drug last year.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A FTC Probe Into GPOs, A Frostbite Drug, And More
The U.S. FTC is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to shortages of key drugs at hospitals.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Slow Uptake Of An Alzheimer’s Drug, An Opioid Lawsuit, And More
Seven months after the FDA fully approved a Biogen treatment for Alzheimer’s disease, only about 2,000 patients are taking Leqembi nationwide.
STAT1 min read
STAT+: Digital Tools Helped Lower Blood Pressure In Marginalized Patient Groups
A new analysis suggests that there ought to be more investment in novel hypertension programs for patients experiencing health disparities.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Tossed PhRMA Lawsuit, Secrecy Clauses, And More
A U.S. district judge granted a Biden administration request to dismiss a PhRMA lawsuit challenging Medicare’s new drug price negotiation program.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Moderna’s RSV Vaccine, Aurobindo Problems, And More
In this morning's Pharmalittle roundup, we're reading about Moderna's RSV vaccine, Aurobindo problems, and more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A U.S. Vaccine Panel, An Abortion Pill, And Much More
A medical journal has retracted two studies claiming to show the harms of the abortion pill mifepristone.
STAT1 min read
Opinion: Moving From Crisis Response To Crisis Prevention In U.S. Mental Health Systems
Despite widespread promises of reform after the murder of George Floyd in 2020, in 2023, police killed at least 1,246 people — the most in more than a decade. This police violence is intertwined with a parallel public policy disaster: America’s abysm
STAT2 min read
STAT+: Pharmalittle: We Are Reading About Catalent Concerns, A Congressional Hearing, And More
The European Medicines Agency will investigate any risks to the availability of medicines processed at Catalent plants that will be sold to Novo Nordisk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Lawsuit Against J&J, Express Scripts Dealings, And More
Johnson & Johnson faces a consequential new class action lawsuit for allegedly overpaying its pharmacy benefit manager for its employees’ medicines.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo Buying Catalent, Amgen’s Obesity Drug, And More
The investment arm of Novo Nordisk’s parent foundation is buying Catalent, a contract development and manufacturing company with more than 50 sites globally.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Opioid Settlements, An OTC Birth Control Pill, And More
A division of the Publicis Groupe and Hikma Pharmaceuticals reached separate settlements worth a collective $500 million to resolve opioid litigation.
STAT1 min read
Opinion: Can Arena Bioworks Upend The Traditional Scientific Research Model In The U.S.?
I’ve spent a good deal of my career thinking about how we structure and fund research in the biomedical sciences in the U.S. and questioning whether the U.S. model of embedding research in universities is the right one. So to me, the launch of Arena
STAT1 min read
STAT+: AI Therapy And ICU Training: A First Look At Health Apps For Apple Vision Pro
Exclusive: Apple works with Cedars-Sinai , Boston Children’s Hospital to develop specialized medical apps for new Vision Pro headset.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Medicare Price Negotiations, Slowing Layoffs, And More
The Biden administration is making its opening offers to pharmaceutical companies in its new Medicare drug price-negotiation program on Thursday.
STAT1 min read
STAT+: Experts Critique Flawed System For Monitoring Drugs’ Side Effects In Wake Of Asthma Drug Report
Experts say that the Singulair incident highlights a flawed system — both in the U.S. and globally — for monitoring adverse reactions after a drug is on the market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy Supplies, Biogen Ditching Aduhelm, And More
Novo Nordisk is increasing availability of its blockbuster obesity drug Wegovy for new patients in the U.S. after a supply crunch led it to limit doses last May.
STAT1 min readChemistry
STAT+: Ultima Genomics Launching High-end DNA Sequencers That Can Read Genome For $100
Upstart sequencing company Ultima Genomics told STAT it will soon launch a line of instruments that can read a human genome for as little as $100.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Vertex Pain Pill, An Abortion Pill Hearing, And More
People who have severe pain but want to avoid the risk of opioid addiction are closer to a new treatment option, after positive study results for a Vertex non-opioid painkiller.
STAT1 min read
STAT+: Vertex Pain Drug Results Met With Measured Optimism — And Questions — By Observers And Experts
Trial results for a pain medication developed by Vertex Pharmaceuticals prompted fresh debate about how widely used the therapy would be should it win regulatory approval.
…Or Discover Something New